

2023 Results and Update



Legal notice

which might occur after this day.

This document and the information contained herein (unless otherwise indicated) have been prepared by Captor Therapeutics S.A. (the "Issuer") solely for informational purposes. For this notice, the presentation that follows shall mean and include the slides that follow, the oral presentation of the slides by the Issuer or any person on behalf of the Issuer, any question-and-answer session that follows the oral presentation, hard copies of this document, and any materials distributed at, or in connection with the presentation (collectively, the "Presentation"). By attending the meeting at which the Presentation is made, or by reading the Presentation, you will be deemed to have (i) agreed to all of the following restrictions and made the following undertakings and (ii) acknowledged that you understand the legal and regulatory sanctions attached to the misuse, disclosure or improper circulation of the Presentation.

The information contained in this Presentation may not be reproduced or redistributed in any way, in whole or in part, to any other person without the prior written consent of the Issuer. This Presentation does not purport to contain all the information that may be required by the recipient to assess the Issuer or its securities. The Issuer prepared this Presentation based on the information which it has and from sources believed to be reliable. To the extent available, the industry, market, and competitive position data contained in this Presentation come from official or third-party sources. There is no guarantee of the accuracy or completeness of such data.

This Presentation contains neither a complete nor a comprehensive financial or commercial analysis of the Issuer, nor does it present its position or prospects in a complete or comprehensive manner. The Issuer has prepared the Presentation with due care, however certain inconsistencies or omissions might have appeared in it. Therefore it is recommended that any person who intends to undertake any investment decision regarding any security issued by the Issuer shall only rely on information released as an official communication (i.e., current/periodic reports) in accordance with the legal and regulatory provisions.

This Presentation may contain certain forward-looking statements, forecasts, estimates, projections, and opinions ("Forward-looking Statements"). By their nature, Forward-looking Statements involve known and unknown risks, uncertainties, assumptions, and other factors because they relate to events and depend on circumstances that will occur in the future whether or not outside the control of the Issuer. No representation is made or will be made that any Forward-looking Statements will be achieved or will prove to be correct. Actual future results and operations could vary materially from the Forward-looking Statements. Similarly, no representation is given that the assumptions disclosed in this Presentation upon which Forward-looking Statements may be based are reasonable. The recipient acknowledges that circumstances may change and the contents of this Presentation may become outdated as a result. The assumptions included herein do not constitute profit forecasts or profit estimates.

No warranties or representations can be made as to the comprehensiveness or reliability of the information contained in this Presentation. Neither the Issuer nor its directors, managers, advisers or representatives of such persons shall bear any liability that might arise in connection with any use of this Presentation. Furthermore, no information contained herein constitutes an obligation or representation of the Issuer, its managers or directors, its shareholders, subsidiary undertakings, advisers or representatives of such persons.

Data contained in this Presentation is valid as of the day of its preparation. Consequently, this Presentation will not be subject to changes, updates or modifications to account for events


This Presentation does not constitute or form part of, and should not be construed as, an offer to sell or issue, or the solicitation of an offer to purchase, subscribe to, or acquire the Issuer or the Issuer's securities, or an inducement to enter into investment activity in any jurisdiction in which such offer, solicitation, inducement or sale would be unlawful before registration, exemption from registration or qualification under the securities laws of such jurisdiction. No part of this Presentation, nor the fact of its distribution, should form the basis of, or be relied on in connection with, any contract or commitment or investment decision whatsoever. This presentation is not for publication, release, or distribution in any jurisdiction where to do so would constitute a violation of the relevant laws of such jurisdiction nor should it be taken or transmitted into such jurisdiction.

2023: a year of progress for Captor

- Secured resources for stable drug candidate development
 - PLN 40M equity raise; PLN 52M ABM grant; rephasing recommendation PLN 4.9M
 - Secure funding till Q3 2025
- CT-01: Growing market with inadequate treatment options; completed GLP regulatory studies, manufacture scale up of drug substance, and appointed global CRO partner to supervise first clinical trial
- CT-03: 2023 data from NHPs and mouse models shows excellent efficacy and selectivity, clean toxicity profile of our first-in-class MCL-1 degrader; IND-enabling studies in 2024
- CT-02; two parallel drug candidate projects:
 - Systemic program targeting autoimmune diseases
 - Brain penetrant program targeting neuroinflammation associated with neurodegenerative disease; growing importance of inflammation in CNS
 - Both programs are currently being tested in disease animal models
- Expanded Business Development collaborations in the USA and China
- Strengthened clinical, business and science teams with international hires



Fully owned pipeline



New members of the leadership team



Andrew Saunders DPM, FFPM Chief Medical Officer

- MB BCh BAO BA, Medicine, Trinity College Dublin
- FFPM, Royal College of Physicians, London
- 25 years' experience in oncology clinical development, including global responsibility for Rituximab



Donald Coppen, Ph.D. **Business Development Director**

- PhD, University of Southampton
- MBA, Cranfield School of Management
- 20 years' experience in business development:
- Biocompatibles plc [Acquired by BTG plc for £177M]
- Algeta ASA [Acquired by Bayer for \$2.9B]
- Consultant to various UK biotechs
- Mereo BioPharma plc [Ultragenyx>\$300M out-license]



Tomas Drmota, Ph.D. **VP Early Discovery**

- PhD, Charles University Prague
- University of Glasgow, Biochemistry and Molecular Biology
- Tufts University, School of Medicine Boston
- 25 years' experience in preclinical drug development for cardiovascular, metabolism, respiratory, autoimmunity and immuno-oncology therapeutic areas

EDUCATION



PREVIOUS EXPERIENCE


























CT-01 (CPT-6281): First-in-Class GSPT1 Targeted Degrader for Hepatocellular Carcinoma (HCC)

CPT-6281 – first-in-class molecular glue degrader for hepatocellular carcinoma




The unique degradation profile of CPT-6281 leads to an Integrated Stress Response (ISR) and induction of apoptosis in HCC cells, while reduction of IL-1 β levels in the tumor microenvironment may enable activation of the immune response

CPT-6281 is a pro-drug activated by an enzyme present at high levels in the liver, lungs and certain gastrointestinal tumors

A unique degradation profile combined with target tissue pro-drug activation for liver, lung, breast and neuroendocrine cancer



Epidemiology of Hepatocellular carcinoma





Current standard of care, changing causality, and opportunity

Line	Therapy	Survival Benefit vs Sorafenib	FDA Approval
1	**TECENTRIQ: + *** AVASTIN** bevacizumab	+5.8 months ¹	Unresectable / metastatic HCC No prior therapy
1	United Street St	+2.7 months ²	Unresectable HCC
1/2	Nexavar (sorafenib) tablets	_3	Unresectable HCC
2	OPDIVO. (nivolumab)	+1.7 months ⁴	Unresectable HCC (Post sorafenib)
2	CABOMETYX* (cabozantinib) tablets	+2.2 months ⁵	Unresectable HCC (Post sorafenib)

Market projections are difficult as there are no truly effective therapies, however global market reports forecast around **15-20% CAGR**

Market Research Provider	Base (Year / \$B)	Future (Year / \$B)	CAGR (%)
Vision Research Reports ⁶	2024: \$3.2	2033: \$11.6	15%
SNS Insider ⁷	2022: \$2.9	2030: \$12.9	20%
Skyquest ⁸	2022: \$2.7	2030: \$11.4	20%
Research and Markets ⁹	2022: \$2.4	2030: \$7.8	15%
Polaris ¹⁰	2021: \$2.2	2030: \$10.4	20%



⁽⁶⁾ https://www.visionresearchreports.com/liver-cancer-drug-market/40952 | (7) https://www.snsinsider.com/reports/liver-cancer-therapeutics-market-3215 | (8) https://www.skyquestt.com/report/liver-cancer-drugs-market

Development status – CPT-6281

In vitro and *in vivo* pharmacology studies

Drug Substance synthesis optimization and manufacture for tox

MTD/DRF tox studies in rats and NHP

DMPK studies

Appointment of CRO to supervise clinical study

GLP tox studies
In-life phase -> completed
Histopathology, TK, safety pharmacology analysis -> ongoing

Drug Substance GMP manufacture

Drug Product development and GMP manufacture

PK & PD assays development for the clinic

Investigator's brochure for clinical trials















Ongoing

Ongoing

Final draft



HCC treatment with a GSPTI degrader - status



Initial indication

Hepatocellular carcinoma

Degradation profile

- GSPTI, NEK7
- Liver and lung activated pro-drug

Strong differentiation from other GSPTI degraders (BMS, MonteRosa)

- Best-in-class degradation profile
- Tissue restrained prodrug expands therapeutic window

Development activities

- GLP-tox and GMP manufacturing complete
- Drug product (capsules) in finalization

Expected milestones in 2024


- Clinical Trial Application submission and approval in Europe
- Initiation of Phase 1 clinical trials in hepatocellular carcinoma in H2





CT-03: First-in-Class MCL-1 Degraders for Liquid & Solid tumors

CT-03: MCL-1 – a critical pathway of cancer resistance



MCL-1 is one of the most amplified proteins in cancer[†]

A critical resistance mechanism in haematological and solid tumors[‡]

Degradation or inhibition of MCL-1 protein directly attenuates tumors in vivo as monotherapy & sensitizes tumors for other therapies

Adequate ablation of MCL-1 requires rapid and sustained action & high target coverage

Use of inhibitors causes accumulation of MCL-1

Degraders have a different mode of action, without accumulation of MCL-1

Degradation of ~70% of MCL-1 induces apoptosis, while inhibitors require almost 100% of target coverage and cause accumulation of the MCL-1

This, together, with optimized clearance expands the therapeutic window from the perspective of toxicity

2. Semin Cancer Biol. 2006 16(4):253-64

- 3. Cell Death Dis 2018 9(2): 19 4. Breast Cancer Res. 2016 18(1): 125
- 5. Int J Mol Sci. 2019 20(3): 5999
- 6. Cell Death Dis. 2022 13(1): 63 7. Colorectal Dis 2022 24(11): 1295-1307

8. Ann Fam Med. 2016 14(3): 215-20 9. Exp Hematol Oncol. 2020 Jun 19;9:14 10.Hum Pathol. 2004 Sep;35(9):1095-100 11.ACS Key Statistics for AML, CLL, Lymphoma 12.Curr Treat Options Oncol. 2020 Jun 29;21(8):66 13.Int J Mol Sci. 2024 Jan 27;25(3):1589 14.Blood Rev. 2020 Nov;44:100672

15.Leukemia. 2013 Jun;27(6):1381-90

†Front Oncol. 2023 Jul 31;13:1226289 ‡Apoptosis. 2023 Feb;28(1-2):20-38



MCL-1: a high potential cancer target

Highly attractive target with application in numerous cancer markets

Haematological malignancies

Multiple Myeloma (MM) Est. \$53B by 2030¹

Acute Myeloid Leukaemia (AML) Est. \$6B by 2028²

Non-Hodgkin Lymphoma (NHL) Est. \$16B by 2032³

Selected solid tumors


Small cell lung cancer (SCLC) Est. \$6.5B by 2031⁴

Non-small cell lung cancer (NSCLC) Est. \$36.9B by 2031⁵

Triple-negative breast cancer (TNBC) Est. \$1.5B by 2030⁶

Despite years of effort from Pharma, no MCL-1 targeting drug has been approved and several inhibitors have been associated with toxicity


Captor has 2 lead degraders, CPT-908 and CPT-2036 and neither has shown any evidence so far of cardiotoxicity in keeping with their different mode of action from inhibitors



Allied Market Research ⁶ Databridge Market Research



Human PBMCs and hiPSC-cardiomyocytes are much less sensitive to degradation




	IC ₅₀ [nM]		
Cell line	CPT-2036	CPT-908	
MV-4-11	119 +/-2.3 (N=21)	3 +/-1.1 (N=3)	
MV-4-11 Ven-resistant	-	0.003	
MV-4-11 Ven-resistant + Venetoclax	-	0.001	
WSU-DLCL-2 (B-cell lymphoma)	3981 +/- 1.6	25 +/- 1.3	
DMS 114	631+/-2.0	16+/-1.3	
OPM-2 (MM)	251+/-1.6	<5 +/- 1.3	
hsPBMC	12589 +/- 5.0	501 +/- 3.2	
hiPSC-CM	15849 +/- 6.3	1585	

PBMCs and hiPSC-cardiomyocytes are much less sensitive than cancer cell lines, even though MCL-1 is degraded



CPT-2036 regresses AML tumors in mice when combined with venetoclax




CPT-2036 was administered 8 times, every 3 days (Q3D) intravenously and venetoclax was administered daily (QD) orally

CPT-2036 in combination with venetoclax strongly inhibits cancer growth in MV-4-11 Human Leukaemia Xenograft Model




Strong PD effect of both CPT-908 & CPT-2036 in vivo (NHP PBMCs)





Cardiotoxicity marker Troponin I in plasma of NHPs after MCL-1 degrader dosing



*Cardiotoxic positive control - Isoproterenol 3mg/kg, Vasopressin 0.3mg/kg



Status: CT-03



• Initial indications

• Blood cancers, subsequently solid tumors

Degradation profile

• Selective first-in-class MCL-1 degraders

Development activities

- Efficacy proven in vivo
- Candidate selection studies underway
- No indicators of cardiac safety issues

Expected milestones

- Candidate selection planned for 2024
- IND-enabling studies 2024





CT-02: First-in-Class NEK7 Degraders for Autoimmune & Neurodegenerative Diseases

CT-02: Vast market potential for inflammasome modulators

Allergy **Asthma Fibrotic** diseases Lupus nephritis **Psoriasis**

Neuroinflammation (AD, PD, MS, ALS)

Myocardial infarction Diabetic cardiomyopathy

> **Inflammatory Bowel Disease**

Gout **Rheumatoid Arthritis** **NEK7** degradation inhibits inflammasome formation and, consequently, the production of inflammatory cytokines leading to the reduction of symptoms of immune-related diseases.

Recent publications demonstrate the potential role of CNS inflammasome in weight loss


Two series of potent NEK7 degraders:


CPT-513 - systemic therapy for the treatment of autoimmune disorders

CPT-101 - therapy of inflammatory neurodegenerative disorders



CPT-513 efficiently covers and degrades NEK7 in NHPs





NEK7 degradation is observed in monkey PBMCs isolated at 3, 6, and 24 h after CPT-513 PO [1 & 3 mg/kg] administration



CT-02: Excellent degraders from two different strategies

Two series of potent NEK7 degraders - in autoimmune diseases (CPT-513) and neurodegenerative disorders (CPT-101, brain-penetrant series)

Activity confirmed both in vitro on mouse, monkey and human cells and in vivo in mice and monkeys

Specificity-driven safety demonstrated in *in vitro* analysis, *in vivo* tolerability studies and confirmed in the clean **CEREP** panel

PK/PD results in monkeys illustrate the attractive features of drug candidates

In vivo proof of efficacy in disease models

SCHEDULED H12024






Finance Highlights

Balance sheet and cash position

Consolidated statement of financial position (PLN, M)



Cash position



* Amount includes grant awarded for phasing in CT-03 project.

R&D costs in 2023

Total: PLN 77.1 M

Net Operational Cash Flow (excluding equity Investment)

Total: PLN 52.2 M

Current (April 2024) guidance indicates cash runway until Q3 2025



Captor Therapeutics®

Captor Therapeutics S.A.

ul. Duńska 11 54-427 Wrocław, Poland

Captor Therapeutics GmbH

Hegenheimermattweg 167A 4123 Allschwil, Switzerland

Contact: investor.relations@captortherapeutics.com

